GenSight Biologics S.A.
GSGTFOTCHealthcare● Active
$0.19
+$0.00(+0.00%)
Market Cap$30986300
P/E Ratio—
52W High$0.48
52W Low$0.1901
GenSight Biologics S.A. (GSGTF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GSGTF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2025Report Date: May 13, 2025EPS Actual
-$0.10
Revenue
$-0.00B
Fiscal Period
Q2 FY2025
FY ends December
Report Date
May 13, 2025
After Market Close
GSGTF reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$3.83
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$3.83
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 23, 2026 | — | — | — | — | — | — |
| ◌ Q3 FY2026 | Jul 23, 2026 | — | — | — | — | — | — |
| — Q2 FY2025 | May 13, 2025 | — | -$0.10 | — | $-0.00B | — | — |
| — Q4 FY2024 | Oct 24, 2024 | — | -$0.07 | — | $0.00B | — | — |
| — Q2 FY2024 | May 29, 2024 | — | -$0.28 | — | $0.00B | — | — |
| — Q2 FY2023 | Jun 30, 2023 | — | -$0.26 | — | $0.00B | — | — |
| — Q1 FY2023 | Mar 24, 2023 | — | -$0.36 | — | $0.00B | — | — |
| — Q4 FY2022 | Oct 28, 2022 | — | -$0.23 | — | $0.00B | — | — |
Q3 FY2026
Jul 23, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2026
Jul 23, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 13, 2025
EPS Actual
-$0.10
EPS Est.
—
EPS Surpr.
—
Revenue
$-0.00B
Q4 FY2024
Oct 24, 2024
EPS Actual
-$0.07
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2024
May 29, 2024
EPS Actual
-$0.28
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2023
Jun 30, 2023
EPS Actual
-$0.26
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q1 FY2023
Mar 24, 2023
EPS Actual
-$0.36
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2022
Oct 28, 2022
EPS Actual
-$0.23
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2025 | May 13, 2025 | — | $0.24 | $0.24 | +0.00% |
| — Q4 FY2024 | Oct 24, 2024 | — | $0.32 | $0.32 | +0.00% |
| — Q2 FY2024 | May 29, 2024 | — | $0.47 | $0.32 | -31.91% |
| — Q2 FY2023 | Jun 30, 2023 | — | $3.10 | $3.10 | +0.00% |
| — Q1 FY2023 | Mar 24, 2023 | — | $3.10 | $3.10 | +0.00% |
| — Q4 FY2022 | Oct 28, 2022 | — | $3.15 | $3.15 | +0.00% |
| — Q2 FY2022 | Apr 21, 2022 | — | $4.75 | $4.75 | +0.00% |
| — Q4 FY2021 | Nov 10, 2021 | — | $8.45 | $8.45 | +0.00% |
Q2 FY2025+0.00%
Report Date
May 13, 2025
EPS Beat/Miss
—
Price Before
$0.24
Price After
$0.24
Q4 FY2024+0.00%
Report Date
Oct 24, 2024
EPS Beat/Miss
—
Price Before
$0.32
Price After
$0.32
Q2 FY2024-31.91%
Report Date
May 29, 2024
EPS Beat/Miss
—
Price Before
$0.47
Price After
$0.32
Q2 FY2023+0.00%
Report Date
Jun 30, 2023
EPS Beat/Miss
—
Price Before
$3.10
Price After
$3.10
Q1 FY2023+0.00%
Report Date
Mar 24, 2023
EPS Beat/Miss
—
Price Before
$3.10
Price After
$3.10
Q4 FY2022+0.00%
Report Date
Oct 28, 2022
EPS Beat/Miss
—
Price Before
$3.15
Price After
$3.15
Q2 FY2022+0.00%
Report Date
Apr 21, 2022
EPS Beat/Miss
—
Price Before
$4.75
Price After
$4.75
Q4 FY2021+0.00%
Report Date
Nov 10, 2021
EPS Beat/Miss
—
Price Before
$8.45
Price After
$8.45
Beat Rate0 / 8 quarters
Largest Move-31.91% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GSGTF ends December
GenSight Biologics S.A. (GSGTF) most recently reported earnings on May 13, 2025 for Q2 FY2025, posting EPS of $-0.10 (in line with the analyst consensus of —). The next GSGTF earnings date is expected around September 1, 2026.
Each quarter, investors track GSGTF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GSGTF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GSGTF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GSGTF earnings · 4 questionsGenSight Biologics S.A.'s next earnings report is expected around September 1, 2026. GSGTF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GSGTF historically reports after market close (AMC).
GSGTF earnings datewhen is GSGTF earningsGSGTF next earnings datewhen does GSGTF report earningsGSGTF earnings calendar
▸ Source: FMP · GenSight Biologics S.A. SEC filings · US GAAP · GenSight Biologics S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026